Richard J Crowley

US Patent:

6368604, Apr 9, 2002

Filed:

Sep 26, 1997

Appl. No.:

08/938106

Inventors:

David M. Hone - Ellicott City MD
Richard Crowley - Gaithersburg MD
George Lewis - Baltimore MD

Assignee:

University of Maryland Biotechnology Institute - Baltimore MD

International Classification:

A61K 3902

US Classification:

4242341, 4242571, 4242581

Abstract:

The present inventors have found that certain preparations containing LPS and/or lipid A variants, derivatives, and/or analogs demonstrate non-pyrogenic properties and exhibit anti-viral activities. In particular, non-pyrogenic preparations of LPS, lipid A, LPS antagonists and lipid A antagonists, and derivatives thereof induce chemokine secretion, such as MIP-1, but not proinflammatory cytokines, such as TNF, IL-1 and IL-6. Non-pyrogenic preparations of the invention have been demonstrated by the Applicant to suppress HIV replication in human peripheral blood monocytes, as described by way of example herein. The present invention provides preparations of LPS or lipid A variants, analogs and derivatives of decreased or absent pyrogenicity which can be used as therapeutics for the treatment or prevention of immunodeficiency virus infection and its consequences.

US Patent:

6596477, Jul 22, 2003

Filed:

Mar 27, 2000

Appl. No.:

09/536668

Inventors:

David M. Hone - Ellicott City MD
Richard Crowley - Gaithersburg MD
George Lewis - Baltimore MD

Assignee:

University of Maryland Biotechnology Institute - Baltimore MD

International Classification:

C12Q 170

US Classification:

435 5, 4242341

Abstract:

The present inventors have found that certain preparations containing LPS and/or lipid A variants, derivatives, and/or analogs demonstrate non-pyrogenic properties and exhibit anti-viral activities. In particular, non-pyrogenic preparations of LPS, lipid A, LPS antagonists and lipid A antagonists, and derivatives thereof induce chemokine secretion, such as MIP- , but not proinflammatory cytokines, such as TNF, IL- and IL- Non-pyrogenic preparations of the invention have been demonstrated by the Applicant to suppress HIV replication in human peripheral blood monocytes, as described by way of example herein. The present invention provides preparations of LPS or lipid A variants, analogs and derivatives of decreased or absent pyrogenicity which can be used as therapeutics for the treatment or prevention of immunodeficiency virus infection and its consequences.

US Patent:

6759241, Jul 6, 2004

Filed:

Feb 27, 2003

Appl. No.:

10/110072

Inventors:

David M. Hone - Ellicott City MD
Richard Crowley - Solana Beach CA
Mohamed Tarek Shata - New York NY

Assignee:

University of Maryland Biotechnology Institute - Baltimore MD

International Classification:

C12N 502

US Classification:

435325, 435 72, 435810, 4241841, 4242341

Abstract:

LPS preparations, isolated from gram negative bacterial strains that contain at least one mutation in at least one of the htrB and msbB genes, and methods and therapeutics related thereto. The LPS preparations display both LPS antagonist and adjuvant activities.

US Patent:

6841345, Jan 11, 2005

Filed:

Aug 26, 1999

Appl. No.:

09/383709

Inventors:

David M. Hone - Ellicott City MD, US
Richard Crowley - Gaithersburg MD, US
George Lewis - Baltimore MD, US

Assignee:

University of Maryland Biotechnology Institute - Baltimore MD

International Classification:

C12Q 170

US Classification:

435 5, 435 72, 435 732, 435 737, 435 41, 43525233, 4242411, 514 54

Abstract:

The present inventors have found that certain preparations containing LPS and/or lipid A variants, derivatives, and/or analogs demonstrate non-pyrogenic properties and exhibit anti-viral activities. In particular, non-pyrogenic preparations of LPS, lipid A, LPS antagonists and lipid A antagonists, and derivatives thereof induce β chemokine secretion, such as MIP-1β, but not proinflammatory cytokines, such as TNFα, IL-1β and IL-6. Non-pyrogenic preparations of the invention have been demonstrated by the Applicant to suppress HIV replication in human peripheral blood monocytes, as described by way of example herein. The present invention provides preparations of LPS or lipid A variants, analogs and derivatives of decreased or absent pyrogenicity which can be used as therapeutics for the treatment or prevention of immunodeficiency virus infection and its consequences.

US Patent:

20040120924, Jun 24, 2004

Filed:

Dec 10, 2003

Appl. No.:

10/732783

Inventors:

David Hone - Ellicott City MD, US
Richard Crowley - Gaithersburg MD, US
George Lewis - Baltimore MD, US

International Classification:

A61K031/739
A61K031/7076
A61K031/7072
A61K038/19

US Classification:

424/085100, 514/054000, 514/046000, 514/050000, 514/220000

Abstract:

The present inventors have found that certain preparations containing LPS and/or lipid A variants, derivatives, and/or analogs demonstrate non-pyrogenic properties and exhibit anti-viral activities. In particular, non-pyrogenic preparations of LPS, lipid A, LPS antagonists and lipid A antagonists, and derivatives thereof induce chemokine secretion, such as MIP-1, but not proinflammatory cytokines, such as TNF, IL-1 and IL-6. Non-pyrogenic preparations of the invention have been demonstrated by the Applicant to suppress HIV replication in human peripheral blood monocytes, as described by way of example herein. The present invention provides preparations of LPS or lipid A variants, analogs and derivatives of decreased or absent pyrogenicity which can be used as therapeutics for the treatment or prevention of immunodeficiency virus infection and its consequences.